This focused issue on “The Evolving Landscape of The Management of Glioblastoma” is edited by Dr. Rimas V. Lukas, Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Dr. Lukas, as Associate Chief of the Neuro-Oncology Division at the Lou & Jean Malnati Brain Tumor Institute of Northwestern University, is interested in the care of patients with primary brain tumors and spinal cord tumors as well as central nervous system (CNS) metastases. Specifically, he enjoys focusing his efforts on translating the discoveries of his basic science colleagues into clinical trials with the goal of improving patient outcomes. Additionally, he has a strong interest in medical education in the U.S. and internationally and conducts research in neuroscience medical education.
Focused issue outline:
- Introduction to this focused issue
- An Overview of Factors Impacting the Research and Clinical management landscape of Glioblastoma
- Revision and Refinement of the Nomenclature of Glioblastoma: Effects on Basic Research and Clinical Practice
- A View of the Epidemiologic Landscape: How Population Based Studies Can Lend Novel Insights Regarding the Pathophysiology of Glioblastoma
- The Role of Extra-CNS Peripheral Immune Cell Trafficking in Patients with Glioblastoma
- The Evolving Role of Anti-Angiogenic Therapies in the Management of Glioblastoma
- Interactions Between Psychological Distress and Immune Functioning in Patients with Glioblastoma
- Integration of Alternating Electrical Fields into Promising Treatment Strategies
- Dose Escalation of Radiation for the Treatment of Glioblastoma
- An Overview of International Outreach in Neuro-Oncology
- Management of Glioblastoma: A Perspective from China
- Management of Glioblastoma: A Perspective from Nigeria
- Management of Glioblastoma: A Perspective from Mexico
- Management of Glioblastoma: An Argentine Perspective
- Management of Glioblastoma: An Australian Perspective
The series “The Evolving Landscape of The Management of Glioblastoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Rimas V. Lukas served as the unpaid Guest Editor for the series.